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INTRODUCTION 
Cognition refers to thinking skills and the intellectual skills that allow a person 
to perceive, acquire, understand and respond to information. This includes the abilities 
to pay attention, remember and process information, solve problems, organize and 
reorganize information, communicate and act upon information.
1 
The disorders that affect cognition include neurodegenerative disorders, 
vascular diseases, trauma, toxin, anoxia and infectious processes.  Cognitive 
impairments are deficits in the processes by which persons perceive, encode, store, 
retrieve and use information. Many processes can lead to cognitive impairment. 
Neurodegenerative disorders that can affect cognitive ability include Alzheimer’s 
disease (AD), Pick’s disease, Parkinson’s disease (PD), Lewy body disease, 
Huntington’s disease, progressive supranuclear palsy and cerebellar degeneration. 
Common vascular disorders that affect cognition include stroke, multiple strokes and 
cerebral embolic disease.  Toxic agents that affect cerebral function (cognition) 
include carbon monoxide poisoning, adverse drug events and interactions and 
prolonged exposure to specific toxic chemicals or gases.  Electrolyte abnormalities, 
organ failure and anoxia can also cause cognitive impairments.
2 
There are two approaches to defining cognitive decline with age: 1) that which 
is considered part of the normal aging process and 2) that which is associated with 
underlying pathology and considered an atypical or abnormal aging process.  From 
the first perspective, cognitive decline has been described as a natural and normal 
process experienced by the aged.  From the second perspective, cognitive decline is 
viewed as a pathological process.   Cognitive decline has also been associated with 
decreased cortical glucose metabolism, heightened protein levels (phosphorylated tau) 
in the cerebral spinal fluid and medial temporal lobe atrophy.
3 
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Depression is the most prominent neuropsychiatric condition associated with 
cognitive impairment. In a study using data from the Canadian Study of Health and 
Aging (CSHA), higher rates of proxy-reported depression, loss of interest and 
changes in personality and mood were noted among cognitively impaired (CI) 
persons, compared to those who were not cognitively impaired (NCI).
3 
 
Role of various neurotransmitters in the cognitive enhancement 
 Aging is one of the most significant risk factors for Alzheimer’s disease (AD). 
When the cognitive functions declines due to aging, it is called as cognitive aging. 
Cognitive function begins to decline in young adulthood, possibly as early as in the 
second or third decade of life. The development of novel cognitive enhancing 
therapies is important for improving function and quality of life for individuals who 
are suffering from cognitive impairment due to cognitive aging or AD.
4 
Acetylcholine 
The neuronal nicotinic acetylcholine receptors (nAChR) is one of the 
important targets for cognitive enhancing therapies. The nAChRs are expressed in the 
hippocampus, a key brain area implicated in cognitive dysfunction in both aging and 
AD. The nAChRs function both presynaptically to regulate neurotransmitter release 
and postsynaptically where they activate intracellular signaling cascades involved in 
learning and memory.    
In addition to nicotinic agonists, M1 muscarinic agonists have the potential to 
boost cognition and slow disease progression. Post synaptic M1 muscarinic 
Acetylcholine (Ach) receptors play a major role in hippocampal based memory and 
learning.
4
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Glutamate  
Glutamate is the major excitatory neurotransmitter and is involved in almost 
all CNS functions, especially in cortical and hippocampal regions. About 70% of all 
excitatory synapses in the CNS utilize Glutamate as neurotransmitter, consistent with 
the involvement of the glutamatergic system in learning and memory. The disturbance 
in Glutamate neurotransmission leads to pathophysiological changes in AD. Chronic, 
mild activation of NMDA receptors ultimately leads to neurodegeneration and this 
effect is termed as chronic ‘Excitotoxicity’.   The prolonged ca2+ overload leads to 
loss of synaptic function followed by synaptotoxicity and ultimately cell death. It 
correlates with the loss of memory function and learning ability in AD patients.
5 
Glutamate can modulate excitatory postsynaptic currents via the metabotropic 
glutamate receptor subtype 5 (mGlu5). Increasing the activation of mGlu5 may offer 
an exciting new therapeutic enhance cognitive function in AD patients. Jeff Conn’s 
group at Vanderbilt University has developed a series of mGlu5 positive allosteric 
modulators for AD, schizophrenia and other neurological conditions.
4
  
Serotonin 
In contrast to direct cholinergic stimulation, another potential therapeutic 
avenue is indirect cholinergic stimulation through 5-hydroxytryptamine (5-HT6) 
receptors. Evidence from cellular and animal models suggest that 5-HT6  receptors 
may enhance cholinergic signaling through glutamatergic and gamma-amino butyric 
acidergic pathways. Both agonist and antagonist ligands of this poorly understood G-
protein coupled recptor have been shown to enhance cognition in preclinical rodent 
models. Several ligands currently in early-phase clinical trials show promise as a 
symptomatic treatment for AD and are also being evaluated in combination with 
AChE inhibitors.
4 
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Dopamine  
Regarding cognitive functions, inactivation of the D1 receptor gene produce 
spatial learning deficits which can be related to the involvement of the D1 receptors in 
working memory processes in the prefrontal cortex (PFC) and to the presence of such 
receptors in the hippocampus. Thus, studies on these receptors should be relevant for 
further characterization of the involvement of Dopamine (DA) in the regulation of 
cognitive processes, as indicated by pharmacological studies. 
The integrative properties of the dopaminergic system are probably associated 
more with direct contributions to cognitive functions at the cortical level, namely in 
working memory, executive functions and possibly time estimation processes.  
Because cognitive impairments occur early in PD, it has been suggested that even 
partial DA depletion limited to the striatal area could contribute to the 
neuropsychological symptoms.  
Since dopaminergic brain activity apparently decreases with normal aging, 
correlated impairment in behavior, such as lack of flexibility and adaptive capacities, 
deficits in selective attention processes or working memory and executive function 
deficiencies, may be related to impairment of central dopaminergic transmission. 
Consequently, stimulating dopaminergic transmission in the elderly could represent a 
reliable strategy for improving behavioral deficits.
6 
 
Nor-adrenaline 
Modulation of noradrenergic system has the potential to be both a 
symptomatic and disease modifying therapeutic strategy. The noradrenergic neurons 
of the locas coeruleus exhibit selective vulnerability during aging, with a significant 
loss of these cells and a decrease in noradrenaline observed in mild cognitive 
 Introduction  
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impairment and AD patients. Noradrenaline is an excitatory neurotransmitter that also 
has anti-inflammatory properties. Regulators of noradrenaline levels are clinically 
approved for use in neuropsychiatric disorders.
4 
Adrenaline  
Adrenaline can produce retrograde enhancement of long term memory in 
humans. An endogenous adrenaline can modulate memory consolidation of the 
events, ensuring memory strength that is proportional to memory importance. There is 
evidence which suggests that adrenaline does have a role in long term stress 
adaptation and emotional memory. Studies have also found that recognition memory 
involving adrenaline depends on the mechanism of β-adrenoreceptors.7        
Though cognition impairment remains a major problem, there are only a few 
drugs available to treat the condition. The drugs available are,    
 a) Cholinergic activators- Tacrine, Rivastigmine, Donepezil, Galantamine 
 b) Glutamate (NMDA) antagonist – Memantine     
 c) Miscellaneous drugs – Piracetam, Pyritinol, Piribedil8   
There are several plants with cognition enhancing and memory improving 
properties. They are, Ginko biloba, Hesperia serrate, Ephedra sinensis, Centella 
asiatica, Acorus calamus, Bacopa monnieri, Withania somnifera and Ginseng.
9 
Ayurveda uses single drug or formulations in age related cognitive decline. 
The drugs mentioned as Meddhya rasayanas specifically and others having medhya 
activity can be potentially used for prevention and management of age related 
cognitive decline. Plants like Centella asiatica, Tinospora carfdifolia, Glycyrrhiza 
glabra are known as   Medhya rasayanas which directly promote cognition. Others 
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such as Brahmi (Bacopa monnieri) and Jyotishmati (Celastrus panniculatus) are 
known for memory improvement.
10 
  
Rasayana is one the eight clinical specialties of classical Ayurveda. Rasayanas 
replenish vital fluids of human body, thus keeping us away from diseases. They 
enhance qualities of rasa, enrich it with nutrients, so that one can attain longevity, 
memory, intelligence, youthfulness, complexion & voice, optimum development of 
physique. Rasayanas are rejuvenators, nutritional supplements and possess strong 
antioxidant activity. Some important Rasayanas are Triphala rasayana, Shilajit 
rasayana, Brahma rasayana and Chyawanprash. The cognition enhancing activity of 
the Rasayanas has also been proved scientifically.
11 
In a recent work, chyawanprash was studied for its beneficial effects on 
cognition in aged animals. It was proved to have memory enhancing property by 
virtue of its antioxidant effect, procholinergic action, increase learning ability and 
increase retention capacity.
12 
 This study attempts to validate the cognition enhancing property of one of the 
commonly used Ayurvedic formulation Brahma Rasayana (BR). 
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REVIEW OF LITERATURE 
Reviews related to Brahma Rasayana 
Praveen Kumar et al., carried out a study on rasayanas including Brahma 
Rasayana. The rasayanas enhanced the humoral immune response as seen from the 
increased number of antibody forming cells and circulating antibody titre. These 
results indicate the usefulness of rasayanas as immunostimulating agent.
13
  
 
Praveen Kumar et al., studied the effect of various rasayanas including 
Brahma Rasayana on tumour bearing mice. Administration of rasayanas had been 
found to enhance the natural killer cell activity in normal as well as in tumour bearing 
animals. Brahma Rasayana was found to have the maximum activity. Brahma 
Rasayana and Ashwagandha rasayanas were found to activate antibody-dependent 
cellular cytotoxicity significantly. All the rasayanas were found to stimulate antibody 
dependent compliment mediated tumour cell lysis. The results of these studies indicate 
the usefulness of rasayanas for immunostimulation in normal and diseased state.
 14
  
Rekha P S et al., reported that 10 and 50 mg/kg dose of Brahma Rasayana 
when given orally showed a significant increase in total leukocyte count and 
percentage of polymorphonuclear cells in irradiated mice. Bone marrow cellularity 
and alpha-esterase positive cells also increased significantly in radiation treated 
animals after Brahma rasayana administration. They also found that, enhanced serum 
levels of interferon-gamma [IFN-] interleukin-2 [IL-2] and granulocyte 
macrophage-colony stimulating factor [GM-CSF] in normal and irradiated mice. 
Therefore, proliferation of stem cells induced by Brahma rasayana in irradiated mice 
might be related to the stimulation of cytokine production.
15
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Rekha P S et al., carried out the study on Brahma Rasayana and reported that 
Brahma Rasayana could reduce the oxygen radicals and subsequently reduce the 
harmful effects produced by the oxygen free radicals mediated injuries.
16 
Thangapazham R L et al., reported that methanolic extract of Brahma 
Rasayana inhibited the proliferation, tube formation, cell migration in a dose 
dependent manner. Their study suggested the possible mechanism(s) of action of 
Brahma rasayana in the reduction of tumour growth and metastatic spread.
17
  
K P Guruprasad et al., carried out the chromosomal aberrations and sperm 
abnormality study on Brahma Rasayana in male Swiss albino mice. They suggested 
that Brahma Rasayana does not elicit genotoxic effects in the mice. It was found to be 
a moderate enhancer of reproductive and mitotic cellularity and a protector against 
certain kinds of sperm abnormality.
18
  
Aditya Menon et al., evaluated the nephroprotective effect of Brahma 
Rasayana using cisplatin induced nephrotoxicity in mice. Administration of Brahma 
Rasayana resulted in the prevention of nephrotoxic effect of CDDP (cis dichloro 
diamine platinumII). They concluded that Brahma Rasayana can be used to prevent 
the side effects of chemotherapeutic drugs.
19
  
Reviews related to key ingredients of Brahma Rasayana 
 Jain NN et al., carried out a study on methanolic extract of Clitoria ternatea 
(CT) on cognitive behavior, anxiety, depression, stress and convulsions induced by 
Pentylenetetrazol (PTZ) and Maximal electroshock (MES). They reported that 
methanolic extract of CT possess nootropic, anxiolytic, antidepressant, anticonvulsant 
and antistress activity.
20
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 Hanumanthachar Joshi et al., carried out a study on Desmodium 
gangeticum (DG) to evaluate the antiamnesic effects in mice. They reported that 
pretreatment with aqueous extract of DG in a dose of 50, 100 and 200mg/kg p.o for 
seven successive days, significantly improved learning and memory in mice and 
reversed the amnesia induced by both scopolamine (0.4mg/kg, i.p) and natural ageing. 
They also suggested that DG decreased whole brain acetylcholinesterase activity.
21
  
  Anil Kumar et al., reported the protective effect of aqueous extract of 
Centella asiatica (CA) against D-Galactose induced behavioral, biochemical and 
mitochondrial dysfunctions in mice. They also reported that animals treated with 
aqueous extract of CA showed significant improvement in behavior alterations, 
oxidative damage and mitochondrial enzyme complex activities.
22
 
 Ferial majed et al., reported that topical application of 30mg/kg of 
Terminalia chebula (TC)  possesses anticarcinogenic effect  and is an effective 
suppressor of oxidative stress against DMBA (7,12-dimethylbenz[a] anthracene ) 
/croton oil induced cutaneous damage. They also suggested that TC could be used for 
the prevention of skin cancer.
23
  
Reviews related to induce cognitive and memory impairment 
There are certain models available to induce the memory and cognitive 
impairments in laboratory animals. They are, 
 β – Amyloid model24,25 
 D-Galactose and AlCl3  model
26-28
 
 D-Galactose model22, 29-31 
 Lead (Pb) model32,33 
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D-Galactose model is a chronic exposure model. It has been used for the 
evaluation of memory and cognitive enhancement properties of various plant extracts 
like Centella asiatica,
22
 Ginkgo biloba,
34
 Curcuma longa,
35
 Artemisia annua L
36
., 
Capparis spinosa L.
37
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AIM AND OBJECTIVE 
Brahma Rasayana is an Ayurvedic formulation, which contains several herbal 
constituents and is marketed for the treatment of drowsiness, fatigue, mental 
weakness, progeriasis, aging and disturbed memory.
38 
Literature review indicates that no specific study has been carried out to 
evaluate the cognition enhancement property of Brahma Rasayana. Some of the 
ingredients used in Brahma Rasayana have been tested for their cognition enhancing 
property.
20-23
 One of the commonly used models to evaluate cognitive impairment is      
D-Galactose model. 
The aim of this study is 
 Evaluation of in vivo cognition enhancing potential of Brahma Rasayana 
using D-Galactose induced memory impaired mice. 
 To elucidate the effect of Brahma Rasayana on various neurotransmitters 
associated with cognitive impairment.  
 Drug Profile  
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DRUG PROFILE 
Brahma Rasayana           
  Ayurvedic system of medicine contains many herbal products for 
natural rejuvenation. Among those products, Brahma Rasayana (BR) is one of the 
most valuable natural remedy for stress and tiredness.  This herbal recipe has been 
prescribed by Lord Brahma. It rejuvenates the body and fights against tiredness, 
fatigue, early grey hairs and wrinkling (Skin rejuvenation and hair rejuvenation). It is 
claimed to be the best anti-aging formula.  It also improves intelligence, memory and 
immune power.
38
 Brahma Rasayana is mentioned in “The Ayurvedic Formulary of 
India”, for the treatment of drowsiness, fatigue/lethargy, tiredness without exertion/ 
languor, mental weakness, senility/ progeriasis, aging and disturbed memory.
39 
The total list of ingredients of Brahma Rasayana are,
38 
 Pathya – Chebulic Myrobalan fruit rind – Terminalia chebula  
 Amalaki – Indian gooseberry fruit – Emblica officinalis Gaertn.   
 Bilwa – Bael (root) – Aegle marmelos 
 Shyonaka – Oroxylum indicum 
 Gambhari – Coomb Teak (root) – Gmelina arboera 
 Patala – Trumpet (root) – Stereospermum suaveolens 
 Agnimantha – Premna corymbosa (Burm.f) Merr 
 Shalaparni – Desmodium gangeticum 
 Prishniparni – Uraria picta 
 Brihati – Indian Nightshade (root) – Solanum indicum 
 Drug Profile  
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 Kantakari – Yellow berried nightshade (whole plant) – Solanum xanthcarpum 
 Bala – Country mallow (root) – Sida cordifolia 
 Punarnava – Spreading Hogweed – Boerhaavia diffusa 
 Eranda – Castor – Ricinus communis 
 Mashaparni – Teramnus labialis / Vigna radiata 
 Mudgaparni – Green gram – Phaseolus trilobus 
 Shatavari – Asparagus racemosus root 
 Meda – Litsea monopetala 
 Jivanti – Leptadenia reticulata 
 Jivaka –  Malaxis acuminata 
 Rishabhaka – Manilkara hexandra (Roxb.) Dubard / Mimusoops hexandra 
Roxb. 
 Shali – Rice – Oryza sativa 
 Kasha – Saccharum spontaneum 
 Shara – Serratophyllum submersom 
 Darbha – Saccharum spontaneum 
 Ikshu – Sugarcane – Saccharum officinarum 
 Twak – Cinnamon – Cinnamomum zeylanicum 
 Ela – Cardamom – Elettaria cardamomum 
 Musta – Nut grass (root) – Cyperus rotundus 
 Rajani  – Turmeric (rhizome) – Curcuma longa 
 Pippali – Long pepper fruit – Piper longum 
 Drug Profile  
 
 Institute of Pharmacology, MMC, Chennai-3. Page 14 
 Agaru – Aquilaria agallocha 
 Chandana – Sandalwood – Santalum album 
 Mandukaparni – Gotu Kola – Centella asiatica 
 Nagakeshara – Mesua ferrea 
 Shankhapushpi – Clitoria ternatea 
 Vacha – Acorus calamus 
 Plava – Nyctanthes arbor-tristis 
 Yashti – Licorice – Glycyrrhiza glabra 
 Vidanga – False black pepper – Embelia ribes 
 Sitopala – Sugar candy  
 Sarpi – Cow ghee  
 Taila – Sesame oil – Sesamum indicum  
 Kshaudra – Honey 
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Table No. 1    Key ingredients of Brahma Rasayana and their pharmacological 
actions
38 
       Name of the ingredient            Pharmacological actions 
Shankhapushpi, Vacha   Excellent memory enhancer and improves 
speaking capabilities.                         
 Amla                          Excellent rejuvenator and anti-oxidant.                     
Pippali,                                    
Ela, Twak                                  
Improve strength of respiratory system. 
Shatavari                   Good for male and female reproductory systems 
and for gastric complaints. 
Punarnava                                                                                   
Ikshu                                                                                                                                           
Musta     
Cleanses and rejuvenates kidney and bladder                                                                   
Bala                                                                        Improves physical and mental strength. 
Vidanga Fights against toxins and microorganisms, bacteria 
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METHODOLOGY 
Experimental animals 
Colony inbred strains of Swiss albino male mice 3-4 weeks old and weighing 
18-24 gm were used in the study. The female mice were not considered because their 
hormonal level changes may influence the cognitive behavior of the animal. Animals 
were obtained from Animal Experimental Laboratory, Madras Medical College, 
Chennai-03. The animals were kept under standard conditions at 23-25
0
C, 12 hour 
light/dark cycle and given standard pellet diet and water ad libitum.  
The animals were acclimatized to the laboratory conditions for a week prior to 
the experimentation. Principles of animal handling were strictly adhered and the 
handling of animals was made under the supervision of Animal Ethics Committee of 
this institute. The experimental protocol was approved by Institutional Animal Ethics 
Committee (IAEC), Madras Medical College, Chennai-03 which is certified by the 
Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA), India.  
Approval. No:  10/243/CPCSEA   dated 10/08/2015 
Pharmacological study: 
Swiss albino male mice weighing 18-24 gm were divided into five groups 
each consisting of six animals. The first group was considered as the control group. 
Cognitive dysfunction was induced by subcutaneous administration of D-Galactose 
continuously for 7 weeks to all the animals except the 1
st
 group.  
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Chronic systemic exposure of mice and rats to D-Galactose causes the 
acceleration of senescence and has been used as an aging model. Chronic D-Galactose 
exposure induces a spatial memory deficit, neurodegeneration by enhancing caspace 
mediated apoptosis. It inhibits neurogenesis and neuron migration, as well as 
increasing oxidative damage and consequent damage of hippocampal neurons by 
triggering apoptosis cascades leading to neuronal loss and cognitive dysfunction.
29
    
 Donepezil (5 mg/kg, p.o) was used as the standard drug for this study. 
Donepezil is a reversible anti-acetylcholinesterase which produces measurable 
improvement in several cognitive as well as non-cognitive scores in AD. The benefit 
is ascribed to elevation of acetylcholine level in the cortex, especially in the surviving 
neurons that project from basal forebrain to cerebral cortex and hippocampus.
40
   
The animals were subjected to treatment with vehicle, Brahma Rasayana (test 
drug) at the dose levels of 1g/kg, 2g/kg p.o and Donepezil (standard drug) 5mg/kg p.o 
for 30 days after induction of cognitive impairment.  The treatment schedule is given 
in Table No 2 
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         Table No.2 Group of animals and their treatment schedule     
S.No Group Number 
of animals 
          Treatment     (Day 50-79)
 
1 Group 1 (control)     6 
 
0.1% w/v of carboxy methyl cellulose 
was given p.o for 30days.  
2 Group 2 (Disease 
control) 
    6 
 
 
 
After 7 weeks, 0.1% w/v of carboxy 
methyl cellulose was given p.o for 30 
days. 
3 Group 3 (Donepezil)     6 After 7 weeks, Donepezil 5mg/kg p.o, 
was administered for 30 days. 
4 Group 4 (Brahma 
Rasayana, low dose) 
   6 After 7 weeks, Brahma Rasayana 
1g/kg p.o, was administered for 30 days. 
5 Group 5 (Brahma 
Rasayana, high dose) 
   6 After 7 weeks, Brahma Rasayana 
2g/kg p.o, was administered for 30 days. 
 
The cognitive impairment in all the groups of animals except Group 1 (control) was 
induced by the administration of D-Galactose (100mg/kg, s.c) daily for 7 weeks 
continuously. (i.e from day 1 to day 49). 
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IN VIVO SCREENING   
Memory and the locomotor activity were evaluated on 0
 
day, 49
th 
and 79
th
 day 
of the study. For assessing memory, Morris water maze and Y-maze test were used. 
The locomotor activity was studied using Open field test and Actophotometer.   
METHODS TO EVALUATE MEMORY 
Morris Water Maze Test
41,42 
The Morris water maze test is performed to evaluate spatial working and 
reference memory. The maze consists of a large circular pool of water with a hidden 
platform. The platform offers no local cues to guide escape behavior. The animals 
when allowed in the pool, can escape from swimming by climbing onto the platform 
and with time the animal apparently learns the spatial location of the platform from 
any starting position at the circumference of the pool.  
Morris water maze consists of a large circular tank (60cm in diameter and 30 
cm in height) made of opaque polyvinyl chloride. The pool is filled up to a height of 
21 cm with water maintained at around 25
0
C and rendered opaque by addition of a 
nontoxic white color (Titanium dioxide powder). The tank was hypothetically divided 
into four equal quadrants and a platform of 19 cm height was placed in the centre of 
one of these four quadrants. The platform remains fixed in the position during the 
training session.  
Each animal was subjected to four consecutive trials for four days during 
which they were allowed to escape on to the hidden platform and allowed to remain 
there for 20 sec. Escape latency time, i.e the time taken to locate the hidden platform 
in water maze was noted as an index of acquisition or learning. In case the animal was 
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unable to locate the hidden platform within 120 sec, it was gently guided by hand to 
the platform and allowed to remain there for 20 sec. The Morris water maze test was 
performed on 0, 49
th
 and 79
th
 day of the experiment for all the five groups of animals.  
Y-maze test 
43,44 
         The continuous spontaneous alternation behavior was evaluated by using Y-
maze apparatus. The Y-maze apparatus was made of black plastic with three arms 
(40cm×15cm×35cm) extending from a central platform at 120
0
. Each mouse was 
placed at the end of one arm and allowed to move freely through the maze during a 
session lasting 5 minutes. Arm entry was defined as the entry of four paws into one 
arm. The sequence of arm entries were recorded visually. Alternation was defined as 
multiple entries into three arms (A, B or C) on overlapping triplet sets. The percentage 
of spontaneous alternation was calculated as the ratio of the actual-to-possible 
alternations (defined as the total number of arm entries minus 2), multiplied by 100, 
as shown in the following equation 
                   
            ( )  [
                      
                   
]       
The Y-maze test were performed on 0, 49
th
 and 79
th
 day of the experiment for 
all the 5 groups of animals.  
 
METHODS TO EVALUATE LOCOMOTOR ACTIVITY  
Open Field Test
45
  
 The open field apparatus was used for the study of locomotor activity. Open 
field apparatus consist of a box 95 cm × 95 cm and a height of 16 cm. The floor was 
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divided into sixteen equal squares by lines drawn on it. A central square was drawn on 
the middle of the open filed. The mice were centrally placed in the open field 
apparatus and were allowed to move without restraint inside the area for 5 minutes 
and ambulation (number of squares crossed by the animal) was noted. 
The animals were exposed for two consecutive days to the apparatus for 
habituation. The open field was cleaned with 5 % water-alcohol solution before 
behavioral testing to eradicate possible bias due to smells left by previous mice. The 
open field test was performed on 0, 49
th
 and 79
th
 day of the experiment in all the         
5 groups of animals.
 
 
Actophotometer
46 
The locomotor activity was measured by using an Actophotometer. The 
actophotometer consists of a square arena (30 × 30 × 25 cm) with wire mesh bottom, 
in which the animal moves. Six lights and six photocells are placed in the outer 
periphery of the bottom in such a way that a single mouse can block only one beam. 
The movement of the animal interrupts a beam of light falling on a photocell, at which 
a count is recorded and displayed digitally. The locomotor activity was measured for a 
period of 5 min. The actophotometer test was performed on 0, 49
th
 and 79
th
 day of the 
experiment in all the 5 groups of animals.  
 
EX VIVO STUDIES 
At the end of study on 79
th
 day, all the animals were sacrificed by cervical 
dislocation followed by decapitation. The whole brain was surgically removed and 
transferred to ice cold saline solution and preserved. This was later subjected to 
neurotransmitter estimation.  
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ESTIMATION OF NEUROTRANSMITTERS  
           Neurotransmitters are endogenous chemicals that transmit signals from a 
neuron to a target cell across a synapse. Glutamate is the major excitatory 
neurotransmitter in the brain and spinal cord.  Excessive glutamate release can lead to 
excitotoxicity causing cell death. Excitotoxicity has been implicated in ceretain 
chronic diseases including ischemic stroke, epilepsy, amyotrophic lateral sclerosis, 
AD, Huntington disease and PD. GABA is released at a majority of fast inhibitory 
synapses in virtually every part of the brain. Many sedative/tranquilizing drugs act by 
enhancing the effects of GABA. Acetylcholine is a neurotransmitter at the central and 
peripheral nervous system. Acetylcholine is involved in memory and attention. 
Dopamine has a number of important functions in the brain. It plays a critical role in 
the reward system but dysfunction of the dopamine system is also implicated in 
Parkinson's disease and schizophrenia. Serotonin is a monoamine neurotransmitter to 
regulate appetite, sleep, memory and learning, temperature, mood, behavior, muscle 
contraction, heart and hormone level. It is speculated to have a role in depression. 
47,48 
         The estimation of Acetylcholinesterase and other neurotransmitter levels was 
carried out by using the isolated whole brain of the mice. The estimation was carried 
out for the following: 
1) Acetylcholinesterase enzyme 
2) Neurotransmitters  
 Glutamate  
 Serotonin  
 Dopamine  
 Adrenaline  
 Nor-adrenaline  
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Estimation of Acetylcholinesterase (AChE) by Ellman’s method 21,49,50 
         Acetylcholinesterase (AChE) is an enzyme which breaks down acetylcholine 
and terminates the neurotransmission process. The most common assay is based on 
Ellman’s method using an alternative substrate acetylthiocholine and 5, 5’-dithio-bis-
2-nitrobenzoic acid (DTNB). The reaction results in production of 5-thio-2-
nitrobenzoate that has yellow color due to the shift of electrons to the sulfur atom.  
Procedure:  
A portion of the brain tissue was weighed and homogenized in 0.1M 
Phosphate buffer (pH 8). 0.4ml aliquot of the homogenate was added to a cuvette 
containing 2.6 ml phosphate buffer (0.1M, pH 8) and 100µl of DTNB. The contents 
of the cuvette were mixed thoroughly and absorbance was measured at 412 nm in a 
spectrophotometer. When the absorbance reached a stable value, it was recorded as 
the basal reading. 20µl of substrate i.e., acetylthiocholine was added and change in 
absorbance was recorded. Change in the absorbance per minute was determined. 
Blank: 0.4ml aliquot of the homogenate was added to a cuvette containing 2.7 ml 
phosphate buffer (0.1M, pH 8) and absorbance was measured at 412nm. 
Calculations 
The enzyme activity was calculated using the following formula 
 
      A/min × Vt 
Acetylcholinestease activity (M/ml) =……………………………. 
      ε × b × Vs 
 where,    
A/min= Change in absorbance per min 
    ε= 1.361 X104 M-1cm-1 
    b= path length  (1 cm) 
    Vt= Total volume (3.1 ml) 
    Vs= sample volume (0.4 ml) 
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The final reading of enzyme activity is expressed as μ moles/minute/mg tissue. 
                                    μ moles /ml sample 
μ moles/minute/mg of protein  =   …………………………… 
                                                     mg of protein /ml sample dilution         
Estimation of Glutamate
51,52
  
A portion of the brain tissue was weighed and homogenized in 0.1M 
Phosphate buffer (pH 8). 1ml of the supernatant from brain homogenate was 
evaporated to dryness at 70°C in an oven and the residue is reconstituted in 100 ml of 
distilled water. Standard solution of glutamate (2.942 mg of glutamate in 10 ml 
distilled water) and tissue homogenate solutions were spotted on Whatman No. 1 
chromatography paper using a micropipette. It was placed on a chamber containing 
butanol: acetic acid: water (12: 3: 5 v/v) as solvent. When the solvent front reached 
the top of the paper, it was removed and dried. A second run was performed similarly, 
after which the papers are dried sprayed with Ninhydrin reagent and placed in an oven 
at 100°C for 4 minutes. The portions which carry glutamate corresponding with the 
standard are cut and eluted with 0.005% CuSO4 in 75% ethanol. Their absorbance is 
read against blank at 515 nm in spectrophotometer. 
Calculation 
The level of glutamate was calculated by using the following formula: 
 
                               Absorbance of test × Standard in mg ×1000 
               A=         …………………………………………………… 
                            Absorbance standard ×Volume spotted (10µl) ×   W 
where, 
A = Amino acid content in µmoles/gram weight tissue 
1000 = Conversion factor for gram wet weight tissue 
W = weight of the tissue in gram 
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Estimation of Serotonin, Dopamine, Adrenaline, Nor-adrenaline
52-55
  
There are two steps in the estimation of neurotransmitters (Serotonin, 
Dopamine, Adrenaline, Nor-adrenaline). The first step of sample preparation is 
common for all the four neurotransmitters and second step is specific to each 
neurotransmitter. 
Preparation of sample solution 
A portion of the brain tissue was weighed and homogenized in 5 ml           
HCl–butanol for about 1 min. The sample was then centrifuged for 10 min at 2000 
rpm. An aliquot supernatant phase (1 ml) was taken and added to centrifuge tube 
containing 2.5 ml heptane and 0.31ml of 0.1 M. HCl. After 10 min of vigorous 
shaking, the  tube  was  centrifuged  under  the  same  conditions  as  above  in  order  
to  separate the  two  phases  and  the  overlaying  organic  phase  was  discarded.  The 
aqueous phase was used for the next step. 
Estimation of Serotonin 
To 0.2 ml aqueous phase (obtained from earlier step), 0.25 ml of OPT (O-
pthalaldehyde) reagent was added. The fluorophore was developed by heating to 
100°C for 10 min. After the samples reached equilibrium with the ambient 
temperature, readings were taken at 360-470 nm in the spectrofluorimeter. For 
serotonin tissue blank, 0.25 ml cont. HCl without OPT was added. Internal Standard: 
500 µg/ml of serotonin was prepared in distilled water: HCl-butanol in 1:2 ratio. 
Estimation of Dopamine  
  To 0.2 ml aqueous phase (obtained from earlier step),  0.05 ml of 0.4 M HCl 
and 0.1 ml of EDTA / Sodium acetate buffer (PH 6.9) were added, followed by 0.1 ml 
iodine solution (0.1 M in ethanol) for oxidation. The reaction was stopped after 2 min 
by addition of 0.1 ml Na2SO3 solution. 0.1 ml Acetic acid was added after 1.5 min. 
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The solution was then heated to 100°C for 6 min. When the sample reached room 
temperature, excitation and emission spectra were read from the Spectrofluorimeter. 
The readings were taken at 330-375 nm. Tissue blanks for Dopamine was prepared by 
adding the reagents of the oxidation step in reversed order (sodium sulphite before 
iodine). Internal Standard: 500 µg/ml each of dopamine was prepared in distilled 
water: HCl-butanol in 1:2 ratio. 
Estimation of Adrenaline and Nor-adrenaline 
 To 0.2 ml aqueous phase (obtained from earlier step), 0.05 ml of 0.4 M HCl 
and 0.1 ml of EDTA / Sodium acetate buffer (PH 6.9) were added, followed by 0.1 ml 
iodine solution (0.1 M in ethanol) for oxidation. The reaction was stopped after 2 min 
by addition of 0.1 ml Na2SO3 solution. 0.1 ml Acetic acid was added after 1.5 min. 
The solution was then heated to 100°C for 6 min. When the sample reached room 
temperature, excitation and emission spectra were read from the Spectrofluorimeter. 
The readings were taken at 395-485 nm. Tissue blanks for adrenaline and nor-
adrenaline were prepared by adding the reagents of the oxidation step in reversed 
order (sodium sulphite before iodine). Internal Standard: 500 µg/ml each of 
adrenaline/ nor-adrenaline was prepared in distilled water: HCl-butanol in 1:2 ratio. 
Statistical analysis 
The statistical analysis was performed using Graph Pad Prism software 
version 5.0. All the results were expressed as mean ± SEM. The data were analyzed 
using one way analysis of variance (ANOVA) followed by Dunnett’s Comparison 
test. The p values <0.05 were considered as statistically significant. 
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RESULTS AND DISCUSSION 
IN VIVO SCREENING  
EVALUATION OF SPATIAL MEMORY 
Morris water maze test 
Morris water maze test is more specific for spatial memory. This test is a 
widely accepted experimental model for the assessment of cognitive skills. Typically, 
cognition impaired induced animals exhibit an increase in time for escape latency 
indicating a loss of visual cues to escape onto the platform. The escape latencies of all 
the animals tested are given in Table 3. 
 
          Table 3:  Effect of BR on Escape latencies of mice in Morris water maze 
S.No Groups Escape latency in seconds  
0 day 49
th
 day 79
th 
day 
1 Control 20±3.73 19.17±2.98 19.33±3.13 
2 Disease control (D-Galactose, 
100mg/kg ) 
21.00±2.37
 
69.33±3.21
*** 
79.00±8.01
*** 
3 Standard (Donepezil, 5 mg/kg) 21.17±2.04
 
69.50±6.96
*** 
22.00±3.88
 
4 BR Low dose  (1g/kg) 20.33±3.94
 
68.67±8.33
*** 
46.17±3.96
** 
5 BR High dose (2g/kg) 20.50±2.93
 
68.50±2.54
*** 
25.17±3.498
 
Values are expressed in Mean ± S.E.M, n=6 *p<0.05, **p<0.01, ***p<0.001.                                             
One way ANOVA followed by Dunnet’s  test. 
 
 From the table no. 3 it can be seen that on day 0, there is no significant 
difference in the escape latency time between the control animals and animals in 
groups II, III, IV and V.    
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On day 49, there was a significant (p< 0.001) increase in the escape latency 
produced by Group II (D-Galactose injected) animals when compared with Group I 
(control) animals. Treatment with BR (1g/kg and 2g/kg, p.o) and standard drug 
Donepezil 5 mg/kg p.o also showed significant (p<0.001, p< 0.001 and p<0.001 for 
Group III, IV and Group V respectively) increase in the escape latency when 
compared with Group I (control) animals. It clearly indicates that D-Galactose 
induced spatial memory deficits in all the animals except the control group.     
 
 
Fig 1: Effects of BR on escape latencies of mice in Morris  water maze test.  
Values are expressed in Mean ± S.E.M, n=6 One way ANOVA followed by Dunnet’s  
test.   
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On day 79, there was a significant (p< 0.001) increase in the escape latency 
produced by Group II (D-Galactose injected) animals when compared with Group I 
(control) animals. There was a significant decrease in escape latency time in standard 
Donepezil treated group of animals. This indicates that Donepezil (5 mg/kg) has 
shown an improvement in cognition. Donepezil is a known anticholinesterase drug 
which is known to inhibit the actions of AChE. It improves Ach levels in the brain 
thus leading to improvement in cognition.  
There was a improvement in the escape latency time but still it was higher 
than the 0 day reading in the BR low dose treated group (1g/kg). In the animals 
treated with the high dose (BR 2g/kg), there was a marked decrease in escape latency 
time. The escape latency time came back near to the 0 day reading.  This clearly 
indicates that BR at the dose of 2g/kg has a significant cognition enhancing potential 
which is comparable with that of the standard drug Donepezil at the dose of 5 mg/kg.  
    Y-Maze test 
Y-maze test is one of the simplest versions of spontaneous alternation test 
which is used to measure memory. The ability to alternate requires the mice to know 
which arm they have already visited. Normal mice are expected to exhibit an 
alternation percentage of 60-70. The animals which were injected with D-Galactose 
had a reduced spontaneous alternation but animals treated with BR produced a 
significant increase in alternation which was comparable to the untreated control 
which in turn indicates the increased spatial working memory of the animals. 
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      Table 4: Effect of BR on spontaneous alternation of mice  in Y-maze                 
S.No Groups Percentage spontaneous alternation   
0
 
day 49
th
 day 79
th 
day 
1 Control 75.25±0.29 76.46±0.57 76.49±0.34 
2 Disease control            
(D-Galactose, 
100mg/kg) 
76.12±0.15
 
11.65±0.24
*** 
10.39±0.25
*** 
3 Standard (Donepezil, 5 
mg/kg) 
75.74±0.50
 
11.67±0.25
*** 
66.03±0.20
*** 
4 BR Low dose (1g/kg) 75.65±0.25
 
12.11±0.42
*** 
51.28±0.31
*** 
5 BR High dose (2g/kg) 75.73±0.39
 
11.83±0.51
*** 
63.26±0.84
*** 
Values are expressed in Mean ± S.E.M, n=6   *p<0.05, **p<0.01, ***p<0.001.                                                      
One way ANOVA followed by Dunnet’s  test. 
From the Table 4, it can be seen that on day 0, there is no significant 
difference in the percentage spontaneous alternation between the control animals and 
animals in groups II, III, IV and V.    
On day 49, there was a significant (p< 0.001) decrease in the percentage 
spontaneous alternation produced by Group II (D-Galactose injected) animals when 
compared with Group I (control) animals. Treatment with BR (1g/kg and 2g/kg, p.o) 
and standard drug Donepezil 5 mg/kg p.o also showed significant (p<0.001, p< 0.001 
and p<0.001 for Group III, IV and Group V respectively) decrease in the percentage 
spontaneous alternation when compared with Group I (control) animals. It clearly 
indicates that D-Galactose induced spatial memory deficits in all the animals except 
control group.   
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  Fig 2: Effects of BR on spontaneous alternation of mice in y-maze test.  Values are expressed in         Mean ± 
S.E.M, n=6    One way ANOVA followed by Dunnet’s  test.  
On day 79, there was a significant (p< 0.001) decrease in the percentage 
spontaneous alternation produced by Group II (D-Galactose injected) animals when 
compared with Group I (control) animals. There was a significant increase in the 
percentage spontaneous alternation in standard Donepezil treated group of animals. 
This indicates that Donepezil (5 mg/kg) has shown an improvement in cognition.  
There was an improvement in the percentage spontaneous alternation but still 
it was lower than the 0 day reading in the BR low dose treated group (1g/kg). In the 
animals treated with the high dose (BR 2g/kg), there was a marked increase in 
percentage spontaneous alternation. This clearly indicates that BR at the dose of 2g/kg 
has a significant cognition enhancing potential which is comparable with that of the 
standard drug Donepezil at the dose of 5 mg/kg. p.o  
    
 
Results and Discussion  
 
 Institute of Pharmacology, MMC, Chennai-3. Page 33 
EVALUATION OF LOCOMOTOR ACTIVITY  
Open field test 
The locomotor activity of the animal was measured by using open field 
apparatus. In this test, the lines crossed by the animals were noted and compared with 
control animals. The units are tabulated in Table 5 
 
Table 5:  Effect of BR on number of line crossings of mice in open field test  
S.No Groups Number of line crossings    
0 day 49
th
 day 79
th 
day 
1 Control 90.17±3.63 75.67±2.75 94.33±2.30 
2 Disease control (D-
Galactose, 100mg/kg) 
86.50±3.99
 
37.50±3.03
*** 
35.00±4.88
*** 
3 Standard (Donepezil, 
5mg/kg) 
89.00±4.95
 
38.67±3.11
*** 
88.00±4.40
 
4 BR Low dose (1g/kg 88.50±4.27
 
38.33±3.21
*** 
84.00±4.27
 
5 BR High dose (2g/kg) 88.17±3.61
 
38.17±2.65
*** 
85.50±4.39
 
Values are expressed in Mean ± S.E.M, n=6   *p<0.05, **p<0.01, ***p<0.001.                                             
One way ANOVA followed by Dunnet’s  test. 
 
From the table 5, it can be seen that on day 0, there is no significant difference 
in the number of line crossings between the control animals and animals in groups II, 
III, IV and V.    
On day 49, there was a significant (p< 0.001) decrease in the number of line 
crossings produced by Group II (D-Galactose injected) animals when compared with 
Group I (control) animals. Treatment with BR (1g/kg and 2g/kg, p.o) and standard 
drug Donepezil 5 mg/kg p.o also showed significant (p<0.001, p< 0.001 and p<0.001 
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for Group III, IV and Group V respectively) decrease in the number of line crossings 
when compared with Group I (control) animals. Cognition is known to induce 
decreased locomotor activity. A decrease in locomotor activity in all the groups which 
were administered D-Galactose indicates development of cognitive impairment.  
 
           
 
Fig 3: Effects of BR on number of line crossings of mice in open field test.   
Values are expressed in Mean ± S.E.M, n=6    One way ANOVA followed by 
Dunnet’s  test.  
On day 79, there was a significant (p< 0.001) decrease in the number of line 
crossings produced by Group II (D-Galactose injected) animals when compared with 
Group I (control) animals. There was a significant increase in the number of line 
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crossings in standard Donepezil treated group of animals. This indicates that 
Donepezil (5 mg/kg) has shown an improvement in cognition. 
There was a good improvement in the number of line crossings and it was near 
the 0 day reading in the BR low dose treated group (1g/kg). In the animals treated 
with the high dose (BR 2g/kg), there was a marked increase in number of line 
crossings as compared to that of the standard treated group. This clearly indicates that 
BR at the dose of 2g/kg has a significant cognition enhancing potential which is 
comparable with that of the standard drug Donepezil at the dose of 5 mg/kg p.o              
Actophotometer  
The locomotor activity of the animals were evaluated by using 
actophotometer. The readings are tabulated in table 6. 
Table 6: Effect of BR on evaluation of locomotor activity using Actophotometer 
S.No Groups Activity scores  
0 day 49
th
 day 79
th 
day 
1 Control 127.5±5.33 117.2±4.03 125.7±8.30 
2 Disease control (D-
Galactose, 100mg/kg) 
121.2±6.23
 
52.33±2.51
*** 
51.83±3.27
*** 
3 Standard (Donepezil, 
5mg/kg) 
124.2±8.34
 
51.67±2.25
*** 
97.50±5.52
* 
4 BR Low dose (1g/kg) 128.2±4.22
 
51.33±2.91
*** 
78.33±8.81
*** 
5 BR High dose (2g/kg) 126.0±6.27
 
51.83±2.59
*** 
95.17±3.13
* 
Values are expressed in Mean ± S.E.M, n=6   *p<0.05, **p<0.01, ***p<0.001.                                                    
One way ANOVA followed by Dunnet’s  test. 
From the table 6, it can be seen that on day 0, there is no significant difference in 
the activity scores between the control animals and animals in groups II, III, IV and V.    
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On day 49, there was a significant (p< 0.001) decrease in the activity scores 
produced by Group II (D-Galactose injected) animals when compared with Group I 
(control) animals. Treatment with BR (1g/kg and 2g/kg, p.o) and standard drug 
Donepezil 5 mg/kg p.o also showed significant (p<0.001, p< 0.001 and p<0.001 for 
Group III, IV and Group V respectively) decrease in the number of line crossings 
when compared with Group I (control) animals.  
            
 
Fig 4: Effects of BR On activity scores of mice in actophotometer.  Values are 
expressed in Mean ± S.E.M, n=6    One way ANOVA followed by Dunnet’s  test.  
 
On day 79, there was a significant (p< 0.001) decrease in the activity scores 
produced by Group II (D-Galactose injected) animals when compared with Group I 
(control) animals. There was a significant increase in the activity scores in standard 
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Donepezil (p<0.05) treated group of animals. This indicates that Donepezil (5 mg/kg), 
a known cognitive enhancer has shown an improvement in cognition.  
There was an improvement in the activity scores in the BR low dose (p<0.001) 
treated group (1g/kg). In the animals treated with the high dose (BR 2g/kg), there was 
a good increase in activity scores compared to that of the standard treated group. This 
clearly indicates that BR at the dose of 2g/kg has a significant cognition enhancing 
potential which is comparable with that of the standard drug Donepezil at the dose of 
5 mg/kg. p.o 
From the above in vivo studies it can be seen that BR at the higher dose of 2 
g/kg is able to improve memory as seen in the Morris water maze and Y-maze studies. 
There is also an improvement in the locomotor activity as seen in the Open field test 
and Actophotometer studies. From this it can be concluded that BR at the dose of 
2g/kg is a cognition enhancer against D-Galactose induced cognition impairment. 
 
EX VIVO SCREENING  
Acetylcholinesterase activity 
Both nicotinic and muscarinic cholinergic receptors are involved in cognitive 
and memory functions and several studies have suggested their roles in dementia. 
Marked cholinergic deficit is a hallmark of the pathogenesis of AD and various drugs 
including AChE inhibitors have been designed to target this deficit. Initially, 
cholinergic deficit was thought to be a muscarinic nature, but recent studies show a 
specific loss of nicotinic acetyl choline receptors and marked loss of cholinergic 
neurons.  
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Table 7: Effect of BR on the amount of Acetylcholinesterase enzyme  
S.No Groups Amount of AChE (µmoles/min/mg of 
protein)  
1 Control 23.11±0.25 
2 Disease control  
(D-Galactose, 100mg/kg) 
32.07±0.13
*** 
3 Standard (Donepezil, 5mg/kg) 24.35±0.23
***
 
4 BR Low dose (1g/kg) 30.83±0.12
***
 
5 BR High dose (2g/kg) 25.95±0.16
***
 
Values are expressed in Mean ± S.E.M, n=6     *p<0.05, **p<0.01, ***p<0.001. 
 One way ANOVA followed by Dunnet’s  test. 
  
 
Fig 5: Effects of BR on the amount of acetylcholinesterase enzyme in mice. 
The enzyme activity is expressed in µmoles/min/mg of protein.  Values are expressed 
in Mean ± S.E.M, n=6    One way ANOVA followed by Dunnet’s  test.  
Results and Discussion  
 
 Institute of Pharmacology, MMC, Chennai-3. Page 39 
 From the Table 7, it is seen that group which is injected with D-Galactose 
there was an increase AChE levels. The level has been significantly reduced in the 
Donepezil (5 mg/kg) treated group. This is expected since Donepezil is a known 
Anticholinesterase agent. 
 In the BR treated group, at the lower dose of 1g/kg the AChE levels showed a 
reduction from the disease group. But in the animals treated with higher dose of BR 
there was a significant reduction in the AChE levels. However this reduction is not on 
par with the standard drug Donepezil.  
 From these results it can be postulated that BR is able to inhibit AChE levels, 
thus increasing the levels of Ach in the brain. 
Glutamate  
The levels of Glutamate in the various groups of animals is given in Table 8. 
 
Table 8: Effect of BR on the level of Glutamate  
S.No             Groups Amount of Glutamate present in µg/mg 
weight of tissue    
1 Control 3.5430 ± 0.16 
2 Disease control (D-Galactose, 
100mg/kg) 
6.3150 ± 0.04
*** 
3 Standard (Donepezil, 5mg/kg) 4.3950 ± 0.03
***
 
4 BR Low dose (1g/kg) 5.3540 ± 0.04
***
 
5 BR High dose (2g/kg) 5.1230 ± 0.06
***
 
Values are expressed in Mean ± S.E.M, n=6      *p<0.05, **p<0.01, ***p<0.001. 
 One way ANOVA followed by Dunnet’s  test 
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Fig 6: Effects of BR On the amount of glutamate in mice.  It is expressed in 
µg/mg wt of tissue.  Values are expressed in Mean ± S.E.M, n=6 .  One way ANOVA 
followed by Dunnet’s  test. 
There was a significant (p< 0.001) increase in the Glutamte levels (µg/mg wt 
of tissue) produced by Group II (D-Galactose injected) animals when compared with 
Group I (control) animals. Treatment with BR (1g/kg and 2g/kg p.o) and standard 
drug Donepezil (5 mg/kg p.o) showed a significant (p<0.001, p< 0.001 and p<0.001 
for Group III, IV and Group V respectively) decrease in the elevated amount of 
Glutamate when compared with Group II (D-Galactose injected) animals. 
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Serotonin, Dopamine, Adrenaline and Nor-Adrenaline 
 The amount of above mentioned neurotransmitters were estimated in the 
isolated brain tissue. The observations are given in Table 9 and Fig 7 
Table 9: Effect of BR on the various neurotransmitters 
S.No Groups      Amount of neurotransmitters present in µg/mg weight of 
tissue    
Serotonin Dopamine Adrenaline Noradrenaline 
 
1 
Control 0.5433±0.01
 
0.2135±0.004 31.99±0.44 114.5±0.89 
2 Disease control 
(D-Galactose, 
100mg/kg) 
0.0698±0.002
***
 0.0407±0.0003
***
 17.74±0.51
***
 65.22±0.83
***
 
3 
 
Standard 
(Donepezil, 
5mg/kg) 
0.3350±0.006
***
 0.1435±0.002
***
 29.48±0.37
***
 96.92±0.64
***
 
4 
 
BR Low dose 
(1g/kg) 
0.2232±0.015
***
 0.0826±0.003
***
 21.50±0.49
***
 82.56±0.61
***
 
5 BR High dose 
(2g/kg)  
0.2763±0.007
***
 0.0895±0.002
***
 27.37±0.39
***
 85.91±1.02
***
 
Values are expressed in Mean ± S.E.M, n=6  *p<0.05, **p<0.01, ***p<0.001.                                     
One way ANOVA followed by Dunnet’s  test 
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                              Fig 7a          Fig 7b 
 
 
         
                        Fig 7c      Fig 7d 
   
Fig 7a,7b,7c,7d :  Effects of BR On the levels of serotonin, dopamine, 
adrenaline and nor-adrenaline in mice respectively.  It is expressed in µg/mg wt of 
tissue.   Values are expressed in Mean ± S.E.M,  n=6 .One way ANOVA followed by 
Dunnet’s  test. 
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There was a significant (p< 0.001) decrease in the amount of serotonin, 
dopamine, adrenaline and nor-adrenaline (µg/mg wt of tissue) produced by Group II 
(D-Galactose injected) animals when compared with Group I (control) animals. 
Treatment with BR (1g/kg and 2g/kg p.o) and standard drug Donepezil (5mg/kg p.o) 
showed a significant (p<0.001, p< 0.001 and p<0.001 for Group III, IV and Group V 
respectively) improvement in the levels of serotonin, dopamine, adrenaline and nor-
adrenaline when compared with group II animals. From the data obtained in table 8 it 
can be concluded that the levels of Serotonin, Dopamine, Adrenaline and Nor-
adrenaline were reduced with the D-Galactose injected group. Donepezil and higher 
dose of BR (2g/kg) treated group of animals, showed a significant increase in 
neurotransmitter levels as compared to group II animals. The lower dose of BR 
(1g/kg) also showed a significant increase in neurotransmitter levels, but it is lesser 
than that of BR higher dose treated animals.   
  
Summary   
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SUMMARY 
 Cognitive impairment is a classic sign of various conditions such as 
Alzheimer’s disease (AD), Pick’s disease, Parkinson’s disease, Lewy body disease, 
Huntington’s disease, progressive supranuclear palsy and cerebellar degeneration. In 
market there are a few drugs available for the improvement of cognition. There are 
several Ayurvedic formulations which are being marketed for this condition. Brahma 
Rasayana is one such formulation with the memory boosting capacity. 
 This study was undertaken to scientifically validate the claim of BR as a 
cognitive enhancer. The model used for the study was the D-Galactose which is one 
of the commonly used models for cognition impairment.  
 Donepezil was used as a standard drug for comparison. The models used to 
test cognition were Morris water maze and Y-maze test for evaluating spatial 
memory, Actophotometer and open field tests were used for evaluation of locomotor 
activity. On all these studies it was seen that BR, especially at the higher dose (i.e 
2g/kg p.o), was able to reverse the cognitive impairment induced by D-Galactose. 
This activity was almost the same as that of Donepezil. 
 In order to establish the mechanism of action, the brain levels of 
acetylcholinesterase (Ach being one of the important neurotransmitters in cognition) 
and neurotransmitters like Serotonin, Dopamine, Adrenaline, Nor-adrenaline and 
Glutamate were estimated. Brahma Rasayana at the higher dose (i.e 2g/kg p.o), showed 
a good anti-cholinesterase activity. The levels of other neurotransmitters like Serotonin, 
Dopamine, Adrenaline, Nor-adrenaline were increased markedly as compared to the 
disease group animals. The level of Glutamate was decreased in Donepezil and BR 
treated group as compared to disease group of animals, which indicates that the 
excitotoxicity of glutamate was reduced by the both standard and BR. 
Conclusion  
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CONCLUSION 
 From the study it is concluded that Brahma Rasayana, which is marketed with 
claims for use in the treatment of drowsiness, fatigue, mental weakness, senility/ 
progeriasis, aging and disturbed memory, has cognition enhancing property at a 
higher dose of 2g/kg and this action is mediated mainly by the Anticholinesterase 
activity. It has also shown an improvement in the levels of neurotransmitters like 
Serotonin, Dopamine, Adrenaline, Nor-adrenaline and Glutamate, which are altered in 
cognition impairment induced by D-Galactose. This study validates the Ayurvedic 
claim of Brahma Rasayana as a memory enhancer. 
 This claim can be further strengthened by carrying out a systematic clinical 
study using Brahma Rasayana in cognition impaired patients. 
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